Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Alzheimer’s Disease (AD) accounts for 60-80% of cases of dementia in people over 65 years of age and affects over 50 million people worldwide and is expected to affect at least 150 million by 2050. Three risk genes, that were identified with strong association with late onset AD, are the topic of this research study – APOE, ABCA7 and PICALM6. Knowledge of the status of individuals at specific loci of these genes is useful in devising precision nutrition and other interventions that might contribute to preventing the development of AD. The intention is to streamline earlier diagnosis of AD which effectively leads to improved patient outcomes following pharmaceutical interventions. In developing this innovative technology to detect AD risk genes rapidly and accurately, revolutionizing the diagnostic process for the at-risk population.
Michelle Bamji-Mirza
GeneRxN Research Corporation
Life Sciences
Professional, scientific and technical services
La Cité
Accelerate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.
Mitacs is funded by the Government of Canada, the Government of Alberta, the Government of British Columbia, Research Manitoba, the Government of New Brunswick, the Government of Newfoundland and Labrador, the Government of Nova Scotia, the Government of Ontario, Innovation PEI, the Government of Quebec, the Government of Saskatchewan, and the Government of Yukon.